| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MANCHESTER, U.K.—Heteronuclear multidimensional NMR has been useful in studies of protein-protein and protein-ligand interactions. For many drug discovery efforts, however, researchers are looking at compounds that interact simultaneously with two proteins—a complex that is difficult to visualize with current isotopic labeling methods. Researchers at the University of Manchester and Bruker Biospin may have found a solution to this technical challenge.
 
As they report in JACS, they used 15N labeling of the protein partners to identify interactions between unlabeled ligand and each protein, but to distinguish the resonances of one protein from the other, they also labeled one with 13C. Thus, the amide peaks of similar residues could be differentiated by the 12C or 13C atom to which they were attached.
 
They tested their isotopically discriminated (IDIS) NMR method on a triple-member complex of 15N-labeled WW domain pair, 13C,15N-labeled receptor peptide, and unlabeled proline-rich peptide. The method allowed them to clearly distinguish the interactions between the three partner molecules at sensitivities only slightly lower than when interactions were examined pairwise. From the researchers perspective, the prime advantage of the new method is that it allows scientists to study multipartner interactions under identical experimental conditions.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Clear cells with round, blue centers are shown against a varied blue background

Supercharging cell line development and engineering with automated single cell sorting

Researchers can enhance efficiency, yield, and consistency in clonal cell line development with specialized tools.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue